�The National Institute of Allergy and Infectious Diseases of the National Institutes of Health has awarded a $2 million subsidisation to Moffitt Cancer Center to study the influences of doctor, patient and policy factors on recommendations of HPV vaccination in the years following licensure of the vaccine.
Principal investigator Susan Vadaparampil , Ph.D., M.P.H., volition focus on physician recommendations of GARDASIL, an HPV vaccine sanctioned by the Food and Drug Administration for use of goods and services in females ages 9 to 26. GARDASIL protects against HPV types 16 and 18, which cause approximately 70 percent of cervical cancers, as well as HPV types 6 and 11, which case approximately 90 percent of genital warts.
Researchers say it is crucial that physicians recommend and advocate for HPV vaccination, but stream rates of immunization for children and adults in the United States ar sub par.
Vadaparampil and her squad will surveil 1,000 physicians in pediatrics, obstetrics/gynecology, and kinfolk and home medicine three years and five years after the vaccine was licensed by the FDA. The goal is to determine how often physicians are recommending the vaccine, as well as what other factors may conduce to vaccinum recommendations.
The $2,079,548 ulysses Grant will fund Vadaparampil's report, "Recommendation of HPV Vaccination Among U.S. Physicians," which will conclude June 30, 2012.
Vadaparampil will lead a team including co-investigators Anna Giuliano , Ph.D.; Ji-Hyun Lee , Ph.D.; and Gwendolyn Quinn , Ph.D. Co-investigators also include Dr. Richard Roetzheim and Dr. Karen Bruder from USF Health; Dr. Neal Halsey from Johns Hopkins Bloomberg School of Public Health ; and Dr. Jessica Kahn from Cincinnati Children's Hospital Medical Center.
About H. Lee Moffitt Cancer Center & Research Institute
Located in Tampa, Florida, Moffitt Cancer Center is the only Florida-based cancer center with the NCI designation as a Comprehensive Cancer Center for its excellence in research and contributions to clinical trials, prevention and cancer control. Moffitt presently has 15 affiliates in Florida, one in Georgia and 2 in Puerto Rico. Additionally, Moffitt is a member of the National Comprehensive Cancer Network, a prestigious alliance of the country's leading genus Cancer centers, and is listed in U.S. News & World Report as one of "America's Best Hospitals" for genus Cancer. Moffitt's sole mission is to put up to the prevention and cure of cancer.
H. Lee Moffitt Cancer Center & Research Institute
View drug information on Gardasil.
More information
